Addressing Real World Challenges
in Osteoporosis

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

November 9, 2009

Expiration Date:

November 9, 2011

Intended Audience:

This symposium has been conceived for the following audience:

• Internal medicine specialists
• Primary care specialists
• Family medicine specialists
• Endocrinologists
• Bone metabolism experts
• Women’s health physicians
• Preventive medicine specialists
• Geriatricians
• Gynecologists
• Osteopathic physicians
• Nurse practitioners
• Geriatric nurse practitioners
• Rheumatologists
• Consulting pharmacists

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Novartis Pharmaceuticals.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Mone Zaidi, MD, PhD, FRCP – Program Chairman
Director, Mount Sinai Bone Program
Professor of Medicine
Mount Sinai School of Medicine
New York, NY

Speaker’s Bureau: Procter & Gamble, sanofi-aventis, Roche, GSK, Novartis

Sol Epstein, M.D.
Clinical Professor of Medicine and Geriatrics
Mount Sinai School of Medicine
New York, New York

Consultant: Roche, GlaxoSmithKline, Merck and Amgen.
Honoraria: Roche/GlaxoSmthKline and Merck

Stuart L. Silverman, MD, FACP, FACR
Professor of Medicine and Rheumatology
University of California, Los Angles
David Geffen School of Medicine
Los Angeles, California

Grant/Research Support: Lilly, Merck, Procter & Gamble, Roche Pharmaceuticals, Roche
Diagnostics, Novartis, Wyeth
Consultant: Merck, Procter & Gamble, Roche Pharmaceuticals, Roche Diagnostics, Novartis, Wyeth
Speakers’ Bureau: Lilly, Merck, Procter & Gamble, Roche Pharmaceuticals

Program Managers and Disclosures

Gideon Bosker, MD
Nothing to Disclose

Milo Falcon
Nothing to Disclose

Denise Leary
Nothing to Disclose

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Learn to stratify patients at risk for osteoporosis and/or related complications and identify optimal therapeutic approaches.
• Learn to undertake a systematic evaluation of patients at risk for osteoporosis, including radiological examination and appropriate laboratory markers.
• Learn evidence-based approaches to reducing progression of osteoporosis, and reducing risk of fracture complications.
• Learn how to select safe and effective pharmacotherapy for prevention and treatment of postmenopausal osteoporosis.
• Learn how landmark trials and analyses focusing on BMD, bisphosphonate therapy, predictive risk, and fracture reduction should guide clinical management of patients with osteoporosis.
  

Disclaimer:

Copyright © 2009 by CMEducation Resources and Pharmatecture, LLC. All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved